
    
      50 adult healthy subjects with 5 dose groups will be enrolled in the study, including six
      subjects in the lowest dose group, four of whom received the SHR-1209 and two of whom
      received the placebo. The other three groups have 11 subjects in each group, 9 administered
      SHR-1222 and 2 administered placebo. The primary endpoint is the Safety and Tolerability :
      adverse events, vital signs, physical examination, laboratory examination, 12 lead
      electrocardiogram, injection site reactions, etc.
    
  